{
    "clinical_study": {
        "@rank": "43585", 
        "acronym": "OAT", 
        "arm_group": [
            {
                "arm_group_label": "Off OAT Group (Test)", 
                "arm_group_type": "Experimental", 
                "description": "Discontinuation of OAT Therapy"
            }, 
            {
                "arm_group_label": "On OAT Group (Control)", 
                "arm_group_type": "Other", 
                "description": "Continuation of OAT Therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to determine the safety of discontinuing oral anticoagulation\n      therapy in high risk patients who have had a successful cardiac ablation and remain AF\n      recurrence free for 3 months post ablation."
        }, 
        "brief_title": "Oral Anticoagulation Therapy Pilot Study", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Paroxysmal Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "detailed_description": {
            "textblock": "Patients undergoing successful cardiac ablation for atrial fibrillation who remain AF\n      recurrence-free 3 months after successful ablation and continue to meet the\n      inclusion/exclusion criteria will be screened for enrollment in the trial. After fulfilling\n      all of the inclusion/exclusion criteria, patients who consent to participate in the study\n      and remain AF recurrence-free will be randomized to one of two study arms: (1) OAT\n      Withdrawal (Test) Group or (2) OAT (Control) Group and participate in the Evaluation Period\n      (12 months)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Successful cardiac ablation for AF\n\n          2. Documented freedom from AF recurrence (symptomatic or asymptomatic arrhythmic\n             recurrences lasting longer than 30 seconds) 3 months after successful cardiac\n             ablation (AF recurrence during 3-month blanking period is excluded).\n\n          3. Patient must have been on a commercially approved anticoagulation therapy for at\n             least two (2) months prior to randomization in the OAT Study.\n\n          4. CHADS2 score \u2265 2 or CHA2DS2-VASc score (\u22653)\n\n          5. Left ventricular ejection fraction > 25%\n\n          6. LA size < 65\n\n          7. High risk for thromboembolic events (i.e., CHADS2 score \u2265 2 or CHA2DS2-VASc score \u2265\n             3) and require OAT before undergoing cardiac ablation\n\n          8. Able and willing to comply with all pre- and follow-up testing and requirements\n\n          9. Signed informed consent form\n\n         10. Age 18 years or older\n\n        Exclusion Criteria:\n\n          1. OAT required for reasons not related to AF (i.e., prosthetic valve, PV stenosis,\n             previous pulmonary embolism, presence of spontaneous echo contrast [SEC] at standard\n             echo performed at 3-months follow-up).\n\n          2. Any cardiac surgery within the past 60 days (2 months) or valvular cardiac surgical\n             procedure at any time (i.e., ventriculotomy, atriotomy, and valve repair or\n             replacement and presence of a prosthetic valve)\n\n          3. Previous myocardial infarction (MI) or a percutaneous coronary intervention PCI\n             within the past 3 months\n\n          4. Awaiting cardiac transplantation or other cardiac surgery within the next 365 days\n             (12 months)\n\n          5. Documented left atrial thrombus\n\n          6. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or\n             COPD) or any other disease or malfunction of the lungs or respiratory system that\n             produces chronic symptoms\n\n          7. Significant medical problem that in the opinion of the investigator would preclude\n             enrollment in this study\n\n          8. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal)\n\n          9. Acute illness or active systemic infection or sepsis\n\n         10. Unstable angina\n\n         11. Contraindication to anticoagulation (i.e., heparin, warfarin or another commercially\n             available anticoagulation medication)\n\n         12. History of blood clotting or bleeding abnormalities\n\n         13. Life expectancy less than 360 days (12 months)\n\n         14. Uncontrolled Heart Failure or NYHA Class III or IV heart failure\n\n         15. Enrollment in a clinical study evaluating another device or drug, within the past 6\n             months\n\n         16. Unable or unwilling to comply with protocol requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959425", 
            "org_study_id": "OAT-149"
        }, 
        "intervention": [
            {
                "arm_group_label": "Off OAT Group (Test)", 
                "description": "Discontinuation of OAT Therapy", 
                "intervention_name": "Off OAT Group (Test)", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "On OAT Group (Control)", 
                "description": "Continuation of OAT Therapy", 
                "intervention_name": "On OAT Group (Control)", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Anticoagulation", 
            "Oral", 
            "Paroxysmal atrial fibrillation", 
            "Patients post successful cardiac ablation", 
            "Symptomatic high-burden paroxysmal AF", 
            "3 months post procedure", 
            "Remain free from AF recurrence"
        ], 
        "lastchanged_date": "March 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160"
                    }, 
                    "name": "University of Kansas Hospitals"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44109"
                    }, 
                    "name": "MetroHealth Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "University of Pennsylvania"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78705"
                    }, 
                    "name": "Texas Cardiac Arrhythmia Research Foundation"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "state": "Pessac", 
                        "zip": "33604"
                    }, 
                    "name": "Le Centre Hospitalier de Bordeaux"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20099"
                    }, 
                    "name": "Asklepios Klinik St. Georg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mestre", 
                        "country": "Italy", 
                        "state": "Venezia", 
                        "zip": "30174"
                    }, 
                    "name": "Ospedale dell'Angelo"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France", 
                "Germany", 
                "Italy"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety of Oral Anticoagulation Therapy Withdrawal After Successful Cardiac Ablation in Patients With Atrial Fibrillation and Associated High Risk Factors for Embolic Events (OAT Pilot Study)", 
        "overall_official": [
            {
                "affiliation": "Texas Cardiac Arrhythmia Research Foundation", 
                "last_name": "Andrea Natale, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Dell'Angelo Hospital", 
                "last_name": "Antonio Raviele, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Pennsylvania", 
                "last_name": "Francis Marchlinski, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hanseatisches Herzzentrum, Asklepios Klinik", 
                "last_name": "Karl Heinz Kuck, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Cardiologigue du Haut-Leveque", 
                "last_name": "Michel Haissaguerre, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Cardiologigue du Haut-Leveque", 
                "last_name": "Pierre Jais, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Dell'Angelo Hospital", 
                "last_name": "Sakis Themistoclakis, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "Italy: Agenzia Italiana del Farmaco", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Composite endpoint represented by the occurrence of any major thromboembolic event (stroke [i.e., ischemic, hemorrhagic or cryptogenic] that is an acute onset of a focal neurologic deficit of presumed vascular origin lasting for \u226524 hours or resulting in death) or major hemorrhagic complication (major bleeding) during the 12-month Evaluation Period.", 
            "measure": "Occurrence of any major thromboembolic event", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959425"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Minor bleeds", 
                "measure": "Bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Hospitalization with any thromboembolic or major hemorrhagic event", 
                "measure": "Hospitalization", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "All cause mortality", 
                "measure": "Mortality", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Quality of Life Questionnaire (SF-36)", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Recurrence of atrial fibrillation- Subject with recurrence of atrial fibrillation will be immediately exited from the study", 
                "measure": "Atrial fibrillation recurrence", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Repeat ablation for atrial fibrillation- Subjects requiring a repeat ablation for AFib will be immediately exited from the study", 
                "measure": "Repeat ablation", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Biosense Webster, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biosense Webster, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}